Science 37® Raises $40 Million to Extend Its Leadership in the Decentralized Clinical Trial Market

On August 20, 2020, the industry leader in decentralized trials, Science 37, announced via PRNewswire that it closed an oversubscribed $40 million funding round. Existing investors Lux Capital, Redmile Group, and PPD, Inc. led the round, and are joined by existing investors Novartis, Amgen, Sanofi Ventures, GV, and Glynn Capital. Notable new investors include LifeSci Ventures and Mubadala Ventures.

“The Science 37 mission to democratize clinical research by bringing trials directly to the patients is not only the right thing to do, but is also has had a clear. measurable impact on sponsors’ ability to access a more diverse patient population, accelerate research, and bring new medicines to the market faster,” said David Coman, CEO of Science 37. “We are thrilled to have an incredibly strong, committed network of investors and plan to continue extending our leadership in the decentralized clinical trial market.”

Science 37 plans to use the new capital to support its rapid growth, expand its technology platform, and accelerate its global expansion efforts- further strengthening its ability to help sponsors execute decentralized trials and enable patients to participate in trials from anywhere, without the burden of traveling to a traditional clinical site.

You can read the full press release here.